Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Results 1 - 20 of 38 : 1 2 Next »

Recs

0
Member Avatar jjc0319 (62.44) Submitted: 6/29/2015 12:26:10 PM : Outperform Start Price: $23.57 DVAX Score: +31.23

Dynavax is near the end of the phase III for Heplisav-B. I feel this drug has a high probability of being approved. Professional targets range between $25-60 a share.

Dynavax has enrollment of 8,000+ subjects in the trial which should be completed late in 2015.The company had submitted Heplisav-B for approval in 2012 but the FDA wanted a larger sample size and rejected it.

The upside is that the drug worked in the smaller study. As the new study is in stage III it indicates the drug is working on a larger scale. This is bio-pharm, so there is always high risk.

The shares topped $45 a share in front of the first trial. I'm hoping to see similar action again this time. If the drug is approved some estimates are $60 for the stock. Again, with a second trial in stage III there is a good chance it will be approved.

The stock has a high beta; so it is volatile. Still, with professional estimates from $25-60 there is a lot of potential upside. I bought in last year under $15 a share and sold @ $24. I jumped back in at various costs between $19-22. At $22.50 a share now there isn't much downside over the next few months. However, when the trials are complete another FDA rejection would be devastating.

I am long DVAX and own shares in my personal portfolio. I hope to add to my possession on price dips.

Recs

1
Member Avatar zzlangerhans (99.76) Submitted: 1/27/2015 3:47:34 AM : Underperform Start Price: $17.49 DVAX Score: -73.31

I gave up on my Dynavax position for a loss long ago, and I'm not seeing much justification for a recent surge in the share price from a steady state at around 14. I think a lot of stocks are benefiting from a January effect and the ones that don't deserve it are going to be hurting when momentum fades. On the other hand, I do think Dynavax is going to be a good trade at some point before the HBV-23 readout at the end of 2015 or early 2016. I think it's highly likely that trial will surmount FDA and EMA objections to Heplisav and finally allow the developmental vaccine into competition with Recombivx and Engerix.The company's Toll receptor modulators in early development are difficult to valuate and could create volatility in either direction over the course of the year.

Recs

1
Member Avatar Patastic (30.01) Submitted: 12/30/2014 12:08:19 PM : Outperform Start Price: $15.13 DVAX Score: +100.38

With the additional Phase 3 safety trial for Hepsilav well under way, things are looking good for this company. $85-$100 price target. My stock pick of the year for 2015.

Recs

0
Member Avatar greg1098 (< 20) Submitted: 8/4/2014 2:16:57 PM : Outperform Start Price: $14.60 DVAX Score: +100.77

the addition of Chief Executive Officer and Director, Eddie Gray, from Dynavax late last yearand previous President of Pharmaceuticals Europe
for GlaxoSmithKline, has renewed vested interest in Hepisav now in phase 3. A large buyout will surely increase stock value.

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 2/21/2014 4:40:48 AM : Outperform Start Price: $19.20 DVAX Score: +47.76

insider heavy buy finviz

Recs

0
Member Avatar SyDVooh (64.03) Submitted: 2/6/2014 11:40:19 AM : Outperform Start Price: $16.90 DVAX Score: +63.50

DVAX has a hepatitis B vaccine that works. It will probably be approved in Europe later this year. That will raise the stock price and make DVAX a takeover target. They are also working on other drugs with GlaxoSmith Kline and Astrazeneca, two solid companies, so it is not a one trick pony as a lot of small cap pharm stocks are. Plus there has been considerable institutional buying lately.

Recs

0
Member Avatar farfetched1 (< 20) Submitted: 11/27/2013 11:08:41 AM : Outperform Start Price: $16.80 DVAX Score: +67.19

With an Initiate out of MFI Capital with BUY $5 dollar price target, I see the price target 12 month of $7-$8 range.

Dynavax has pioneered a new approach in their quest for therapies dealing with multiple autoimmune and inflammatory diseases including lupus, psoriasis, and rheumatoid arthritis.

Dynavax technology consists of oligonucleotide-based immunoregulatory sequences (IRSs) that inhibit Toll-like Receptors (TLRs) 7, 8, and/or 9. TLRs are key receptors of the innate immune system that can induce strong inflammatory responses.

Their TLR inhibitors have demonstrated a highly targeted effect on key immune cells and pathways that play a role in multiple autoimmune and inflammatory diseases. In contrast, most currently marketed and in their pipeline products are broadly immunosuppressive with variable efficacy and substantial toxicity.

Under their worldwide strategic alliance with GlaxoSmithKline (GSK), established in 2008, they are developing DV1179, a bi-functional inhibitor of TLR7 and TLR9. In a 2010 article published in NATURE, Dynavax scientists showed that activation of the innate immune system by TLR7 and TLR9 can cause glucocorticoid resistance in lupus patients. This resistance was reversed by Dynavax's novel TLR7/TLR9 inhibitors in both human blood cells and in vivo animal models of lupus.

In October 2011, based on novel preclinical data, Dynavax announced the expansion of their alliance with GSK to include TLR8 as a new target. The activation of TLR8 in myeloid cells yields the production of multiple pro-inflammatory cytokines, including tumor necrosis factors (TNFs), IL-1, IL-6 and IL-12. They will further evaluate the hypothesis that inhibition of TLR8 could prevent the inflammatory cascade initiated by these cytokines in many autoimmune conditions.

Under the terms of Dynavax alliance, GSK can exercise its exclusive option to license each program upon achievement of certain events, and they are eligible to receive option exercise payments. Dynavax are also eligible to receive tiered, up to double-digit royalties on sales and have retained an option to co-develop and co-promote one product.

IN SUMMARY

Recent Phase 1 and 2 are showing extremely promising war chest with their partnerships with

The Th1 Response

The Th1 response involves the production of the body’s most potent anti-infective weapons – specific cytokines, including interferon-alpha, interferon-gamma and interleukin 12 (IL-12), as well as killer T cells, a specialized immune cell. In addition, the Th1 response generates IgG antibodies to help rid the body of foreign antigens and allergens. Once a population of Th1 cells specific to a particular antigen or allergen is produced, it persists for a long time in the form of memory Th1 cells, enabling a more rapid and powerful immune response the next time exposure to that particular antigen or allergen occurs. An insufficient Th1 response to an infection can result in chronic disease, whereas an inappropriate Th1 response can cause diseases such as rheumatoid arthritis.
The Th2 Response

Activation of the Th2 response involves the production of other cytokines, IL-4, IL-5 and IL-13, which attract inflammatory cells, such as eosinophils, basophils and mast cells, to destroy the invading organism. The Th2 response also leads to the generation of IgE, a specialized antibody that can recognize antigens and allergens and further enhance the protective response. An inappropriate Th2 immune response to allergens, such as plant pollens, can lead to chronic inflammation resulting in allergic rhinitis, asthma and other allergic diseases. Subsequent exposures to the same allergens can reactivate memory Th2 cells, sustaining inflammation and leading to chronic disease.

Keep this one on your rare finds ready to take off on a early entry of currently $1.55 - $1.75 range.

Recs

1
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:30:28 PM : Underperform Start Price: $13.50 DVAX Score: -102.68

Short. Biopharma. Revs down. Selling more and more stock.

Recs

0
Member Avatar whoodatstockhot (92.92) Submitted: 7/9/2013 11:31:37 AM : Outperform Start Price: $11.60 DVAX Score: +135.76

Big upside here, solid management team, nice catalysts, and dirt cheap.

Recs

0
Member Avatar swa5469 (< 20) Submitted: 5/16/2013 12:15:06 PM : Outperform Start Price: $24.95 DVAX Score: -0.66

Good drugs in the pipe-line. Once management stabilizies and Europe comes on board, we should see some nice positive movement upwards.

Recs

0
Member Avatar adfishow (32.36) Submitted: 3/16/2013 10:10:45 PM : Outperform Start Price: $21.30 DVAX Score: +10.63

It's a speculation but I believe teh drug wil be approve and a big money maker

Recs

1
Member Avatar genedom (98.35) Submitted: 2/20/2013 2:53:41 AM : Outperform Start Price: $29.90 DVAX Score: -30.57

FDA will approve the better HBV vaccine this time, even with a post trial.

Recs

0
Member Avatar warrenicahn (65.52) Submitted: 1/2/2013 10:10:53 AM : Outperform Start Price: $29.25 DVAX Score: -35.42

New drug will receive approval in February, and two other new drugs in phase 1 will make this a valuable company.

Recs

0
Member Avatar SamsaricSufferer (48.43) Submitted: 11/17/2012 12:08:52 PM : Outperform Start Price: $25.00 DVAX Score: -25.44

Bounce play on a fundamentally sound company.

Recs

0
Member Avatar Beststocks99 (47.66) Submitted: 3/8/2012 11:58:06 AM : Outperform Start Price: $41.70 DVAX Score: -74.29

Things are working with the FDA

Recs

0
Member Avatar helpmesav (< 20) Submitted: 12/31/2011 12:32:50 PM : Outperform Start Price: $33.70 DVAX Score: -67.64

Heplisav will be approved last quarter 2012 and their pipleine is strong

Recs

0
Member Avatar Bumkinpops (< 20) Submitted: 9/21/2011 7:30:43 PM : Outperform Start Price: $19.60 DVAX Score: -23.50

Lead product Heplisav should be approved as efficacy, safety and manufacturing consistency all appear to have been achieved. FDA submition within 3 months and significant advantages over current market leader engerixB. This product alone justifies three times the current market cap. Add to that the pipeline, most significanlty the Universal flu vaccine, based on the same technology that created Heplisav.

Recs

0
Member Avatar KimLanners (< 20) Submitted: 7/20/2011 12:04:39 PM : Outperform Start Price: $25.20 DVAX Score: -32.14

biot

Recs

0
Member Avatar bruceedge (< 20) Submitted: 6/19/2011 2:15:36 PM : Outperform Start Price: $25.70 DVAX Score: -41.56

good pipeline in the works and a good technical chart cupping around it's 200 day M.A.

Recs

0
Member Avatar Fuzzy114 (< 20) Submitted: 4/6/2011 4:33:58 PM : Outperform Start Price: $27.80 DVAX Score: -42.28

Very good sponsorship by institutional funds. Employees enjoy partnership in ownership. They are burning rubber.
Would not like to be short Dvax.
Fuzzy114

Results 1 - 20 of 38 : 1 2 Next »

Featured Broker Partners


Advertisement